Nurse Practitioner Program year 2024 Reported 2021–2024 Source: CMS Open Payments, 2026 publication

Rachael Hueftle

Nurse Practitioner Reno, NV Nurse Practitioner

NPI 1881857472 CMS profile 11107364

10791 Double R Blvd, Reno, NV 89521

Open in the dashboard

General payments

$6,672

280 records reported · program years 2021–2024

Research payments

$0

Paid to them · None reported · program years 2021–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Rachael Hueftle of Reno, NV is reported in the CMS Open Payments database as having received $6,672 across 280 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $270 7
2023 General $68 2
2022 General $1,676 65
2021 General $4,658 206

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rachael Hueftle
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Rachael Hueftle were reported at $0. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Rachael Hueftle Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $4,658 $135 $40–$426 $132
2022 $1,676 $152 $48–$470 $149
2023 $68 $166 $54–$529 $160
2024 $270 $173 $55–$556 $164
2025 $0 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2024
  1. Janssen Pharmaceuticals, Inc $1,360 49 payments
  2. Sunovion Pharmaceuticals Inc. $1,156 57 payments
  3. Neurocrine Biosciences, Inc. $723 13 payments
  4. AbbVie, Inc. $611 44 payments
  5. Otsuka America Pharmaceutical, Inc. $595 24 payments
  6. Alkermes, Inc. $480 13 payments
  7. ITI, Inc. $356 12 payments
  8. Supernus Pharmaceuticals, Inc. $348 17 payments
  9. Abbott Laboratories $256 7 payments
  10. Eisai Inc. $238 17 payments
  11. Other $550 27 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2024
  1. Food and Beverage $6,669 279 payments
  2. Education $3 1 payment
Products named General payments · program years 2021–2024
  1. LATUDA $1,156 57 payments
  2. INVEGA SUSTENNA $1,081 45 payments
  3. SPRAVATO $751 26 payments
  4. INVEGA TRINZA $647 22 payments
  5. VRAYLAR $611 44 payments
  6. REXULTI $385 15 payments
  7. INGREZZA Neurology $369 9 payments
  8. CAPLYTA $356 12 payments
  9. INGREZZA Neuropsychiatry $354 4 payments
  10. ARISTADA INITIO $343 11 payments
  11. Other $3,722 137 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

162

Median for Nurse Practitioner: 389

Drug cost

$1,331

Median for Nurse Practitioner: $21,885

Branded share of claims

20.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Pregabalin Generic 15 $266
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 20 $232
Gabapentin Generic 36 $204
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 13 $162
Methocarbamol Generic 17 $161
Methylprednisolone Generic 27 $156
Cyclobenzaprine Hcl Generic 14 $91
Tramadol Hcl Generic 20 $60

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 29 billing codes

Paid by Medicare

$23,234

Of which drugs: $116

Medicare patients

242

Average age 74

Services billed

616

128 women, 114 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 70%
Diabetes 24%
Ischemic heart disease 24%
Osteoporosis 24%
Depression 18%
Chronic kidney disease 16%
Atrial fibrillation 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, bupivicaine, not otherwise specified, 0.5 mg J0665 Office 11 17 $0

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

280 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Nevada

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record